Drug class: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors Mechanism of Action Ceritinib is a tyrosine kinase inhibitor (TKI) that selectively targets anaplastic lymphoma kinase (ALK), a transmembrane receptor involved in cell growth and survival, as well as insulin‑like growth factor‑1 receptor (IGF‑1R), insulin receptor (InsR), and ROS1 (1, 2). By inhibiting ALK autophosphorylation, ceritinib disrupts downstream signaling pathways, particularly STAT3, thereby s